Developer docs
API playgroundTry for free, no card

Search company profiles

Biotheranostics

Full company profile

uuid0003q69

Namestring
Biotheranostics
Legal namestring
Biotheranostics, Inc.
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Biotheranostics is a commercial-stage molecular diagnostics company headquartered in San Diego, California, that develops and operates proprietary gene-expression-based laboratory tests for oncology treatment decision-making. The company runs a CLIA-certified laboratory offering two flagship assays: the Breast Cancer Index (BCI), which is the only genomic test with dual recognition from both ASCO and NCCN Clinical Practice Guidelines for predicting benefit from extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer patients, and CancerTYPE ID, positioned as the most validated gene-expression assay for identifying tumor type and subtype in metastatic cancer patients presenting with unknown or unclear primary diagnoses. Both tests are deployed through a sales-led, direct-to-provider model in which oncologists, breast-cancer specialists, and pathologists order tests via the Hologic Provider Portal and patients interact with a separate payment portal (dxlink.com), with revenue generated through per-test laboratory service fees rather than disclosed subscription or enterprise contracts. Biotheranostics was acquired by Hologic, Inc. (NASDAQ: HOLX) in February 2021 and continues to operate as a wholly-owned subsidiary within Hologic's Diagnostics segment, with active clinical-evidence generation including 11 studies at the 2025 San Antonio Breast Cancer Symposium and a registry study presented at the 2026 ASCO Annual Meeting demonstrating material shifts in physician treatment recommendations following BCI testing.

Short descriptiontext

Biotheranostics is a San Diego-based, Hologic-owned molecular diagnostics company that operates a CLIA-certified lab providing two proprietary gene-expression tests — Breast Cancer Index and CancerTYPE ID — to oncologists for personalized treatment decisions in HR+ breast cancer and metastatic cancer of unknown primary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular cancer diagnostics, genomic oncology testing, breast cancer assays, tumor profiling services, gene expression diagnostics
Industry4 codes
PRIMARYHLAKAFAJ
Breast Oncology
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Oncology Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Testing Services
TypeSubscription Recurring
Description

Biotheranostics provides genomic testing services to healthcare providers and patients, generating revenue through laboratory service fees for the Breast Cancer Index and CancerTYPE ID tests

biotheranostics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Breast Cancer Index
Description

The only genomic test recognized by ASCO and NCCN Clinical Practice Guidelines to help predict benefit of extended endocrine therapy in HR+, early-stage breast cancer.

biotheranostics.com
+1 more record
Core offering1 text field

Biotheranostics operates a CLIA-certified laboratory that provides two proprietary gene expression-based genomic tests to support oncologists' treatment decisions. The Breast Cancer Index (BCI) test predicts benefit of extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer patients, while the CancerTYPE ID assay identifies tumor type and subtype in metastatic cancer patients with unknown or unclear diagnoses.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Physician recommendations for extended endocrine therapy increased by over 30% for patients identified as likely to benefit following BCI testing
+1 more record
Product overview1 text field

Biotheranostics offers a portfolio of proprietary genomic assays for personalized disease management in oncology. The company provides two core genomic tests: the Breast Cancer Index (BCI) test for predicting extended endocrine therapy benefit in HR+ early-stage breast cancer, and the CancerTYPE ID assay for identifying tumor types and subtypes in metastatic cancer patients with unknown diagnoses. Both products use gene expression analysis to guide treatment decisions. Biotheranostics was acquired by Hologic in February 2021.

Product and service2 records
1Breast Cancer Index (BCI)
CategoryGenomic Assay
Description

A proprietary gene expression-based genomic test recognized by both ASCO and NCCN Clinical Practice Guidelines that helps predict benefit of extended endocrine therapy in hormone receptor-positive (HR+), early-stage breast cancer patients. Used by oncologists and breast cancer specialists to personalize treatment duration decisions.

2CancerTYPE ID
CategoryGenomic Assay
Description

A proprietary gene expression-based assay described as the most validated of its kind that helps identify the tumor type and subtype for metastatic cancer patients with unknown or unclear diagnoses, supporting personalized treatment selection by oncologists and pathologists.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-01
Description

Hologic acquired Biotheranostics in February 2021. Biotheranostics continues to operate as a subsidiary offering its portfolio of proprietary genomic assays for personalized disease management in oncology, leveraging Hologic's broader diagnostics infrastructure and market presence.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Myriad Genetics offers hereditary cancer testing (BRACAnalysis) and oncology molecular diagnostics, competing in similar oncology specialist channels and serving overlapping breast and metastatic cancer patient populations.

TypeDirect peer
Description

Veracyte (including the NanoString Prosigna acquisition) markets the Prosigna Breast Cancer Prognostic Gene Signature Assay, a direct competitor to BCI for HR+ early-stage breast cancer risk of recurrence assessment.

TypeBroad incumbent
Description

Foundation Medicine, a Roche subsidiary, provides comprehensive genomic profiling for solid tumors including FoundationOne CDx, overlapping with Biotheranostics' CancerTYPE ID for metastatic cancer molecular profiling and tumor characterization.

TypeEmerging player
Description

Natera offers oncology molecular testing including Signatera for MRD monitoring and broader tumor profiling, competing in the oncology molecular diagnostics space where Biotheranostics operates.

TypeEmerging player
Description

Guardant Health offers liquid biopsy-based oncology testing including tumor profiling for advanced cancers, representing an emerging technology approach that competes with tissue-based assays like CancerTYPE ID and could encroach on BCI's market.

TypeDirect peer
Description

Exact Sciences develops and commercializes the Oncotype DX Breast Recurrence Score test, the most entrenched competitor to Biotheranostics' Breast Cancer Index for guiding extended endocrine therapy decisions in HR+ early-stage breast cancer.

TypeDirect peer
Description

Agendia offers MammaPrint and BluePrint genomic assays for breast cancer recurrence risk and molecular subtyping, directly competing with Biotheranostics' BCI in the same oncologist customer base for early-stage breast cancer treatment decisions.

TypeBroad incumbent
Description

NeoGenomics is a clinical oncology laboratory offering comprehensive oncology testing services including molecular and genetic profiling, competing broadly with Biotheranostics' specialty genomic assays while serving a wider oncology menu.

TypeDirect peer
Description

Caris provides molecular profiling and tumor type identification services for metastatic and cancers of unknown primary, directly overlapping with CancerTYPE ID's use case for oncologists dealing with unclear diagnoses.

10Tempus AI
TypeEmerging player
Description

Tempus provides multi-modal oncology testing including molecular profiling and tumor type identification for metastatic cancer, competing with CancerTYPE ID for cancer of unknown primary workups.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biotheranostics

Molecular Oncology Diagnosticsbiotheranostics.com

Biotheranostics is a San Diego-based, Hologic-owned molecular diagnostics company that operates a CLIA-certified lab providing two proprietary gene-expression tests — Breast Cancer Index and CancerTYPE ID — to oncologists for personalized treatment decisions in HR+ breast cancer and metastatic cancer of unknown primary.

What Biotheranostics does

Biotheranostics is a commercial-stage molecular diagnostics company headquartered in San Diego, California, that develops and operates proprietary gene-expression-based laboratory tests for oncology treatment decision-making. The company runs a CLIA-certified laboratory offering two flagship assays: the Breast Cancer Index (BCI), which is the only genomic test with dual recognition from both ASCO and NCCN Clinical Practice Guidelines for predicting benefit from extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer patients, and CancerTYPE ID, positioned as the most validated gene-expression assay for identifying tumor type and subtype in metastatic cancer patients presenting with unknown or unclear primary diagnoses. Both tests are deployed through a sales-led, direct-to-provider model in which oncologists, breast-cancer specialists, and pathologists order tests via the Hologic Provider Portal and patients interact with a separate payment portal (dxlink.com), with revenue generated through per-test laboratory service fees rather than disclosed subscription or enterprise contracts. Biotheranostics was acquired by Hologic, Inc. (NASDAQ: HOLX) in February 2021 and continues to operate as a wholly-owned subsidiary within Hologic's Diagnostics segment, with active clinical-evidence generation including 11 studies at the 2025 San Antonio Breast Cancer Symposium and a registry study presented at the 2026 ASCO Annual Meeting demonstrating material shifts in physician treatment recommendations following BCI testing.

Biotheranostics firmographics

Firmographics
Name
Biotheranostics
Legal name
Biotheranostics, Inc.
Website
https://biotheranostics.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
51–100 employees
Short description
Biotheranostics is a San Diego-based, Hologic-owned molecular diagnostics company that operates a CLIA-certified lab providing two proprietary gene-expression tests — Breast Cancer Index and CancerTYPE ID — to oncologists for personalized treatment decisions in HR+ breast cancer and metastatic cancer of unknown primary.
Ownership category
akta.pro rank

Biotheranostics industry classification

Industry
Product category
Molecular Oncology Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAKAFAJ
Breast Oncology
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Molecular cancer diagnostics
  • Genomic oncology testing
  • Breast cancer assays
  • Tumor profiling services
  • Gene expression diagnostics

Where Biotheranostics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Biotheranostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Testing Services: Biotheranostics provides genomic testing services to healthcare providers and patients, generating revenue through laboratory service fees for the Breast Cancer Index and CancerTYPE ID tests

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Biotheranostics product offering

Product offering

Core offering

Biotheranostics operates a CLIA-certified laboratory that provides two proprietary gene expression-based genomic tests to support oncologists' treatment decisions. The Breast Cancer Index (BCI) test predicts benefit of extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer patients, while the CancerTYPE ID assay identifies tumor type and subtype in metastatic cancer patients with unknown or unclear diagnoses.

Product overview

Biotheranostics offers a portfolio of proprietary genomic assays for personalized disease management in oncology. The company provides two core genomic tests: the Breast Cancer Index (BCI) test for predicting extended endocrine therapy benefit in HR+ early-stage breast cancer, and the CancerTYPE ID assay for identifying tumor types and subtypes in metastatic cancer patients with unknown diagnoses. Both products use gene expression analysis to guide treatment decisions. Biotheranostics was acquired by Hologic in February 2021.

Differentiator

Problem solved

Functional benefit

Brands

  • Breast Cancer Index: The only genomic test recognized by ASCO and NCCN Clinical Practice Guidelines to help predict benefit of extended endocrine therapy in HR+, early-stage breast cancer.
  • CancerTYPE ID

Products and services

  • Breast Cancer Index (BCI) A proprietary gene expression-based genomic test recognized by both ASCO and NCCN Clinical Practice Guidelines that helps predict benefit of extended endocrine therapy in hormone receptor-positive (HR+), early-stage breast cancer patients. Used by oncologists and breast cancer specialists to personalize treatment duration decisions.
  • CancerTYPE ID A proprietary gene expression-based assay described as the most validated of its kind that helps identify the tumor type and subtype for metastatic cancer patients with unknown or unclear diagnoses, supporting personalized treatment selection by oncologists and pathologists.

Quantifiable outcome

  • Physician recommendations for extended endocrine therapy increased by over 30% for patients identified as likely to benefit following BCI testing
  • +1 more outcomes

Companies that use Biotheranostics

Customer profile

Segments2 records

Ideal customer profiles2 records

Biotheranostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Biotheranostics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HologiccoreStrategic or Co-development Partner · 1 February 2021Hologic acquired Biotheranostics in February 2021. Biotheranostics continues to operate as a subsidiary offering its portfolio of proprietary genomic assays for personalized disease management in oncology, leveraging Hologic's broader diagnostics infrastructure and market presence.

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Biotheranostics competitors and assessment

Company assessment

Direct peers

  • Myriad Genetics: Myriad Genetics offers hereditary cancer testing (BRACAnalysis) and oncology molecular diagnostics, competing in similar oncology specialist channels and serving overlapping breast and metastatic cancer patient populations.
  • Veracyte: Veracyte (including the NanoString Prosigna acquisition) markets the Prosigna Breast Cancer Prognostic Gene Signature Assay, a direct competitor to BCI for HR+ early-stage breast cancer risk of recurrence assessment.
  • Exact Sciences: Exact Sciences develops and commercializes the Oncotype DX Breast Recurrence Score test, the most entrenched competitor to Biotheranostics' Breast Cancer Index for guiding extended endocrine therapy decisions in HR+ early-stage breast cancer.
  • Agendia: Agendia offers MammaPrint and BluePrint genomic assays for breast cancer recurrence risk and molecular subtyping, directly competing with Biotheranostics' BCI in the same oncologist customer base for early-stage breast cancer treatment decisions.
  • Caris Life Sciences: Caris provides molecular profiling and tumor type identification services for metastatic and cancers of unknown primary, directly overlapping with CancerTYPE ID's use case for oncologists dealing with unclear diagnoses.

Broad incumbents

  • Foundation Medicine (Roche): Foundation Medicine, a Roche subsidiary, provides comprehensive genomic profiling for solid tumors including FoundationOne CDx, overlapping with Biotheranostics' CancerTYPE ID for metastatic cancer molecular profiling and tumor characterization.
  • NeoGenomics: NeoGenomics is a clinical oncology laboratory offering comprehensive oncology testing services including molecular and genetic profiling, competing broadly with Biotheranostics' specialty genomic assays while serving a wider oncology menu.

Emerging players

  • Natera: Natera offers oncology molecular testing including Signatera for MRD monitoring and broader tumor profiling, competing in the oncology molecular diagnostics space where Biotheranostics operates.
  • Guardant Health: Guardant Health offers liquid biopsy-based oncology testing including tumor profiling for advanced cancers, representing an emerging technology approach that competes with tissue-based assays like CancerTYPE ID and could encroach on BCI's market.
  • Tempus AI: Tempus provides multi-modal oncology testing including molecular profiling and tumor type identification for metastatic cancer, competing with CancerTYPE ID for cancer of unknown primary workups.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Biotheranostics compliance and trust

Trust signal

Compliance1 record

Biotheranostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biotheranostics leadership team

Management profile

Number of profiles

Profiles2 records

Biotheranostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biotheranostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotheranostics

What does Biotheranostics do?

Biotheranostics operates a CLIA-certified laboratory that provides two proprietary gene expression-based genomic tests to support oncologists' treatment decisions. The Breast Cancer Index (BCI) test predicts benefit of extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer patients, while the CancerTYPE ID assay identifies tumor type and subtype in metastatic cancer patients with unknown or unclear diagnoses.

Is Biotheranostics a public or private company?

Biotheranostics is a private company. It is classified as corporate owned and is currently operating.

When was Biotheranostics founded?

Biotheranostics was founded in 1996. It employs 51 to 100 people.

Where is Biotheranostics based?

Biotheranostics is headquartered in San Diego, United States, in the North America region.

How does Biotheranostics make money?

One revenue line is on record: laboratory Testing Services.

Who are Biotheranostics's main competitors?

Direct peers on record are Myriad Genetics, Veracyte, Exact Sciences, Agendia and Caris Life Sciences. Broad incumbents are Foundation Medicine (Roche) and NeoGenomics. Emerging players are Natera, Guardant Health and Tempus AI.

Does Biotheranostics have an API?

No public API is recorded for Biotheranostics.

What industry is Biotheranostics in?

Biotheranostics's product category is Molecular Oncology Diagnostics. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerHologic, Inc. and Biotheranostics, Inc. Announce Updated Breast Cancer Index Test Report Option and Jama Network Open DataHologic and Biotheranostics published JAMA Network Open data showing the Breast Cancer Index test led physicians to change extended endocrine therapy recommendations for 42% of patients, with two-thirds of those changes against treatment. The findings come from a registry study of nearly 3,000 patients, and an updated report option is now available as of July 2026.MarketScreenerHologic and Biotheranostics Present New Data on Breast Cancer Index Test At Asco 2026Hologic and Biotheranostics presented new data on the Breast Cancer Index test at ASCO 2026, showing physician recommendations for extended endocrine therapy increased by over 30% for patients likely to benefit and decreased by nearly 40% for those unlikely to benefit. The data come from a new analysis of the BCI Registry Study, with findings presented on June 1.Business Wire BlogNew Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy DurationHologic, Inc. and its subsidiary Biotheranostics announced that 11 studies on the Breast Cancer Index (BCI) Test will be presented at the 2025 San Antonio Breast Cancer Symposium, covering expanded utility in premenopausal women and comparisons to the 21-gene assay for endocrine therapy decisions. One key study found the BCI Test may identify premenopausal patients with early-stage HR+ breast cancer who are at minimal risk of metastatic recurrence, potentially allowing some patients to avoid more aggressive treatment regimens. The test, which has been used by over 9,000 providers over the past decade, is the only guideline-recognized biomarker to predict which early-stage HR+ breast cancer patients may benefit from extended endocrine therapy.MarketScreenerNew Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy DurationHologic, Inc. and its subsidiary Biotheranostics announced that 11 studies on the Breast Cancer Index (BCI) Test will be presented at the 2025 San Antonio Breast Cancer Symposium, exploring expanded utility in premenopausal women and comparisons with the 21-gene assay. The research includes findings from analyses of major clinical trials and real-world data supporting the test's ability to guide extended endocrine therapy decisions for early-stage hormone receptor-positive breast cancer patients. The presentations underscore continued clinical evidence generation for the test, which is already used by over 9,000 providers and holds guideline recognition from ASCO and NCCN.Military and Veteran Benefits5 New Genetic Diagnostic Tests to Be Covered by TricareThe Defense Health Agency extended a pilot program covering over 45 laboratory-developed tests through July 18, 2028, adding five new genetic tests for breast, blood, and prostate cancers and suspicious skin lesions. The update includes the Biotheranostics Breast Cancer Index, DermTech Pigmented Lesion Assay, and FoundationOne Heme test, with coverage effective January 1, 2023.Amboy Street VenturesAmboy Street VenturesMedical device company Alydia Health was acquired by Organon for $240 million, with the transaction closing after Organon spun off from Merck in June 2021; Alydia Health's Jada System is designed to stop postpartum hemorrhage by encouraging normal uterine contraction after childbirth. The article positions this acquisition within a broader trend of consolidation in the women's health and sexual health medical device space, citing similar moves by Hologic, which acquired Sometex Medical for $64 million and Biotheranostics for approximately £230 million. The analysis highlights multiple startups innovating across fertility, contraception, maternity, and pelvic health, suggesting increased M&A activity is expected in this sector over the next five years.PR NewswireOutlook on the Breast Cancer Diagnostics Global Market to 2028 - by Product, Type, Application, End-use and RegionResearch and Markets published a global breast cancer diagnostics market analysis report projecting the market to reach USD 6.8 billion by 2028, expanding at a 7.0% CAGR from 2021 to 2028, driven by technological advancements such as 3D mammography and increased breast cancer awareness. The report highlights key strategic moves including Exact Sciences' acquisition of Genomic Health in November 2019 and Hologic's agreement to acquire Biotheranostics for approximately USD 230 million in January 2021, alongside product launches from Fujifilm, Myriad Genetics, and QIAGEN. Market growth is expected to be tempered by risks associated with radiation exposure and contrast agents used in imaging and diagnostic procedures.BenzingaMedTech Round Up: Update On Products By Biomerica, 908 Devices, Ekso Bionics, Hologic - Biomerica (NASDAQBiomerica announced an update to its COVID-19 Antigen Rapid Test allowing for nasal swabs, while 908 Devices updated its MX908 handheld mass spec device with new detection modules and Bluetooth capabilities. Ekso Bionics expanded its partnership with Kindred Healthcare to deploy robotic exoskeletons in four U.S. hospitals, and Hologic's subsidiary Biotheranostics received broader Medicare coverage for its Breast Cancer Index test.GlobeNewswireBiotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine TherapyThe National Comprehensive Cancer Network (NCCN) added Breast Cancer Index to its breast cancer guidelines as the only gene expression assay for predicting benefit from extended endocrine therapy in early-stage hormone receptor-positive breast cancer. The recommendation covers node-negative and node-positive patients across Tamoxifen and Aromatase Inhibitor regimens, based on MA.17, Trans-aTTom, and IDEAL studies.BenzingaThe Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping - iShares BiotechnologyThis article is a daily roundup of multiple unrelated developments in the biotechnology sector, including Aerpio's strategic review and positive glaucoma trial results, Hologic's acquisition of Biotheranostics, and Myriad Genetics' restructuring. It also covers clinical milestones for AIM ImmunoTech and Stealth BioTherapeutics, as well as financial updates from NeoGenomics and TransEnterix. The report aggregates various corporate actions without focusing on a single dominant event.